Thomas H. Carter

<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Guido Marcucci, Kati Maharry, Yue-Zhong Wu et al. · Journal of Clinical Oncology · 2010 · 757 citations · Full text

Favorable Prognostic Impact of <i>NPM1</i> Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

Heiko Becker, Guido Marcucci, Kati Maharry et al. · Journal of Clinical Oncology · 2009 · 339 citations · Full text

<i>TET2</i> Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Klaus H. Metzeler, Kati Maharry, Michael D. Radmacher et al. · Journal of Clinical Oncology · 2011 · 319 citations · Full text

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

Klaus H. Metzeler, Heiko Becker, Kati Maharry et al. · Blood · 2011 · 274 citations · Full text

<i>RUNX1</i> Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures

Jason H. Mendler, Kati Maharry, Michael D. Radmacher et al. · Journal of Clinical Oncology · 2012 · 265 citations